Theratechnologies Inc T.TH

Thank you

[scarlet1967]

Theratechnologies Inc.

Discontinuing Research Coverage

Our view:

We are discontinuing research coverage of THTX due to reallocation of

analyst resources. Our final rating is Sector Perform with a final price target

of $2.00.

Investment summary

Our final rating on the stock is Sector Perform, and our final price target

is $2.00 / share.

Our view has been that sales of Trogarzo in HIV and Egrifta in lipodystrophy

provide stable cash flows to fund operations and additional pipeline

opportunities for the company, such as the upcoming NASH trial and

promising sortilin oncology program, and that recent commercial efforts

have yielded improvements. However, our view has been that the

current share price accurately balances unknowns about the long-term

competitiveness of Trogarzo, potential patent cliffs for Egrifta, high-risk

nature and unclear regulatory path for NASH, and early stage of the

oncology portfolio.

[jfm1330]

In a nutshell you have it. You wonder why the were forced into the last financing? You have it there. To agree or not is something else, but you have the widespread view in the market.

[SPCEO1]

It is one thing for RBC to have a heavily negative slant on every aspect of TH but it is quite another for the company to effectively confirm those negative views by doing an offering that put no value at all on their pipeline. The company did a lot of good things to put a very intriguing pipeline in place for very little shareholder funds expended but they fell flat on their face when trying to

[jfm1330]

I understand your frustration with the RBC analyst, but the fact is that now he is no longer alone in his skeptic view of Thera. The management did not recognized that view in doing the financing, they recognized it was the general view of the market and made the financing to mitigate the financial risks. They know they won't have meaningful data to share before the summer or even the fall. It

[SPCEO1]

It is certainly frustrating but I do not agree that they will not have any data to share before the Summer or Fall. Whatever issues remain outstanding with the FDA on NASH could be resolved well before that, removing any remaining uncertainty from skeptics on that front. On cancer, they are targetting speaking again at the AACR conference which is being held from April 9-14. They have laready

[Wino115]

I am hopeful that is all to be.  As the WallStreetBets boys would say....To The Moon!

[jfm1330]

I was talking about meaningful data. AACR we already know what it will be, good pre-clinical data in other cancers than those already published. On the clinical trial in oncology, I doubt they will rush publicly at the first early sign of efficacy, if it happens, in the dose escalation phase. They are likely to wait for data with the therapeutic dose. So it is likely to go to the fall. Clear

[qwerty22]

SPCEO I think you are getting aggressive on your cancer expectations, from what you've written on timetables it looks optimistic. I disagree with Jfm I think they will announce efficacy signals as they appear. It seems to be how oncology proceeds. The fact that the regulatory process is more fluid, Ph2 can rapidly develop out of a Ph1 signal, makes these material facts so there's a real

[SPCEO1]

Qwerty, you and JFM both know the science better than I do, obviously, but I do have some questions for you. You indicated I was too aggressive but then seemed to agree with what I was saying when you disagreed with JFM - am I missing something there? Do you agree or disagree with the possibility we may get some feedback about the pahse I trial from the dosing portion of the trial? Or are you

[qwerty22]

I have to say I mis-read what jfm wrote, I thought he'd said they would wait until the end of dose escalation. I actually completely agree with Jfm, when I wrote 6-9 months I meant from the start of the trial so that matches jfm's timeline of Fall. What you write might be right but the absolute earliest they might get a report of a shrinking tumour, I don't think they report at that

[scarlet1967]

Paul said he is going to accelerate the process even so Jim doesn't agreed with me what I heard was he described the dosing and early data as upcoming milestones so my take is they will announce any progress as soon as possible now exactly when nobody knows not even the company but I am pretty sure they are eager to announce early news. As per holes for NASH we can speculate the size of them

[palinc2000]

Whatever hole there is we know it is NOT a sink hole....I have not seen any subsequent studies since the decision to go for General Nash which has shown a worsening of the odds of success,,,On the contrary !!!!!  The decision was based on strong recommandations by Grinspoon and lLoomba and probably others .....They know what they have and they know what they dont have,,,,Why would they spend

[scarlet1967]

I posted a couple of research articles published in 2021 emphasizing the role of insulin resistance, mitochondrial dysfunction, pro inflammatory proteins and adipose tissue in causation of NAFLD/NASH quite inline with company's proposed MOA of their protocol and they proved that on HIV liver which because of the virus and ART drugs  has more fat deposition than normal liver so the holes

[Bucknelly21]

sent this to Phillipe  You guys have not participated in the bubble beside from taking easy money in what appears to be a really bad deal for long term shareholders and a great deal for banks who appear to keeping the market warrants and selling everything else. I hope I’m wrong. I hate to say it but it’s true, no real value for shareholders other that hope one of the things in the

[scarlet1967]

Great we want proactive company we need to be proactive too I have sent many emails to IR too and don't care if she refuses to respond."bugging Theratechnologies mode".

[canadapiet]

I did the same + wrote about examples of capital increase done by other companies way better for existing shareholders..........! No answer yet. Scarlet: RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Thank you Great we want proactive company we need to be proactive too I have sent many emails to IR too and don't care if she refuses to respond."bugging Theratechnologies mode"

[Bucknelly21]

Not expecting an answer, I know he reads them because once in a while he replies with something short and some what irritated lol

[Bucknelly21]

If you don't want to be irritated then produce it's very simple, they have cost most here with the exception of a few lots of opportunities to make money on our investment. It cannot go on any longer. There are too many companies I see with small caps that take off with nothing but a couple pr's about barely anything of substance. I don't buy the "share price isn't high

[palinc2000]

Those research articles that you posted are very helpful and again why would the Kol s reccommend spending tens of millions in a trial if in fact there is a gaping hole,,,,They made a lousy deal and even an extremely lousy deal  but IT IS NOT BECAUSE THERE IS A GAPING HOLE IN THE DATA..... [/quote]

[scarlet1967]

I agree the data with or without holes haven't changed they got the go a head for straight phase 3 but they need to adjust the proposed protocol or maybe they need to adjust it to get EMA on board too as there was an agreement between two agencies few years ago so they could align their strategies. It's not lousy data it's lousy marketing efforts for years which is the issue. It almost

[SPCEO1]

While you never like to lose coverage from a good analyst, this is clearly a positive development. In his final comments, he revealed again how he always was looking at the worst case scenario for TH rather than something more balanced. On Trogarzo, the early indications are that Fostemsavir has not caused it any problems and there are not any other competitive drugs on the horizon. On the

[scarlet1967]

My dog is better looking than him, on a serious note the IR department needs to shift their strategies as they seem not to be able her reputable and engaged analysts on board. I say it again like have been pitching for a long long tine the importance of getting the powerful retail investors on board first, get the demand, volume and SP where it should be and the analysts will be joining the

[Wino115]

Thank you...next.  As if we didn't know the entire arrangement with RBC was a quid pro quo for the convertible deal.  They got their fee and then became a petulant child when they weren't rewarded again in this deal.  It's is not a coincidence this came out a few weeks after the deal - they were sidelined by a recalcitrant analyst who refused to even look at the future.

[scarlet1967]

Please send it to Leah and dubuc Too....